FYI

September 2011

May 2011
The FDA is allowing Dendreon, the manufacturer of Provenge, to expand production by more than double to increase availability of the intravenously injected treatment for prostate cancer.

March 2011
Dr. Mark S. Soloway, Professor and Chairman Emeritus, Department of Urology and his associates at the Miller School of Medicine, mailed a survey questionnaire to 185 men enrolled in active surveillance (AS) at their university-based urological oncology practice. The questionnaire asked whether the men had been offered AS as an alternative to primary treatment by the urologist who initially diagnosed their cancer, and what other factors contributed to their decision.

February 2011
The risk of breast cancer, for women who have at some time been bothered by hot flashes and other menopausal symptoms caused by lower estrogen levels, may be reduced as much as 50 percent, researchers from the Fred Hutchinson Cancer Research Center in Seattle report.